Prelude Therapeutics Incorporated (PRLD)
PRLD moved a median of 0.00% 30 minutes after news, and -1.02% by the close. How PRLD actually reacts to news — the realized, point-in-time move the market made, measured across 237 labeled events over the last three years with zero look-ahead.
PRLD’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 30% | 231 |
| 30-min | 0.00% | 47% | 236 |
| 60-min | -0.44% | 42% | 237 |
| to close | -1.02% | 44% | 236 |
| Middle 50% of PRLD reactions | -1.69% to +2.36% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 237 |
Half of all Prelude Therapeutics Incorporated news events land between -1.69% and +2.36% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How PRLD reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 11 | +0.55% | 55% | -1.70% |
| Rating reiterations | 32 | +0.38% | 59% | -0.33% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how PRLD ranks against every other measured name →
That’s how PRLD usually reacts — get an email when it moves on news →Email me when PRLD moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PRLD's baseline. Nothing else.
Recent PRLD events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Prelude Therapeutics to Participate in the Chardan Healthcare Conference | Press release | GlobeNewswire | +1.22% | +3.35% | |
| Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer | Press release | GlobeNewswire | +2.94% | -4.81% | |
| Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference | Press release | GlobeNewswire | +0.63% | -2.75% | |
| Form 8-K Prelude Therapeutics For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | -1.79% | -7.34% | |
| Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader | Press release | GlobeNewswire | -1.79% | -7.34% | |
| Form 10-Q Prelude Therapeutics For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.91% | +7.47% | |
| Form 8-K Prelude Therapeutics For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | -0.91% | +7.47% | |
| Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -0.91% | +7.47% | |
| Form 8-K Prelude Therapeutics For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | -1.01% | +4.05% | |
| Form 10-Q Prelude Therapeutics For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.04% | -3.33% | |
| Form 8-K Prelude Therapeutics For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -1.04% | -3.33% | |
| Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -1.04% | -3.33% | |
| Form ARS Prelude Therapeutics For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -4.42% | +15.71% | |
| Form DEF 14A Prelude Therapeutics For: Jun 09 | SEC filing · Form DEF | SEC EDGAR | -4.42% | +15.71% | |
| Form DEFA14A Prelude Therapeutics | SEC filing · Form DEFA14A | SEC EDGAR | -4.42% | +15.71% | |
| Form 8-K Prelude Therapeutics For: Apr 20 | SEC filing · Form 8-K | SEC EDGAR | -4.05% | -1.49% | |
| Form 8-K Prelude Therapeutics For: Apr 20 | SEC filing · Form 8-K | SEC EDGAR | +1.20% | -9.80% | |
| Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering | Press release | GlobeNewswire | +1.20% | -9.80% | |
| Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026 | Press release | GlobeNewswire | +1.20% | -9.80% | |
| Form 8-K Prelude Therapeutics For: Apr 15 | SEC filing · Form 8-K | SEC EDGAR | +3.69% | +27.19% | |
| Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer | Press release | GlobeNewswire | +3.69% | +27.19% | |
| Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting | Press release | GlobeNewswire | +0.00% | -9.04% | |
| Form 8-K Prelude Therapeutics For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | -1.49% | -1.49% | |
| Form 10-K Prelude Therapeutics For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +5.35% | +20.40% | |
| Form 8-K Prelude Therapeutics For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | +5.35% | +20.40% | |
| Form S-8 Prelude Therapeutics | SEC filing · Form S-8 | SEC EDGAR | +5.35% | +20.40% | |
| Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026 | Press release | GlobeNewswire | +5.35% | +20.40% | |
| Form 8-K Prelude Therapeutics For: Jan 29 | SEC filing · Form 8-K | SEC EDGAR | +6.34% | +11.71% | |
| Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor | Press release | GlobeNewswire | +6.34% | +11.71% | |
| Form 8-K Prelude Therapeutics For: Jan 09 | SEC filing · Form 8-K | SEC EDGAR | -1.08% | -5.40% | |
| Form EFFECT Prelude Therapeutics | SEC filing · Form EFFECT | SEC EDGAR | -1.97% | -3.94% | |
| Form S-3 Prelude Therapeutics | SEC filing · Form S-3 | SEC EDGAR | +0.91% | -1.21% | |
| Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs | Press release | GlobeNewswire | -0.67% | -2.67% | |
| Form 10-Q Prelude Therapeutics For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.72% | +6.52% | |
| Form 8-K Prelude Therapeutics For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | -0.72% | +6.52% | |
| Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -0.72% | +6.52% | |
| Form 8-K Prelude Therapeutics For: Nov 03 | SEC filing · Form 8-K | SEC EDGAR | -5.66% | -16.98% | |
| Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors | Press release | GlobeNewswire | -5.66% | -16.98% | |
| Prelude Therapeutics Announces Strategic Business Update | Press release | GlobeNewswire | -5.66% | -16.98% | |
| Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting | Press release | GlobeNewswire | +3.17% | +151.90% | |
| Form 8-K Prelude Therapeutics For: Oct 15 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -8.46% | |
| Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors | Press release | GlobeNewswire | +0.00% | -8.46% | |
| Form 8-K Prelude Therapeutics For: Sep 18 | SEC filing · Form 8-K | SEC EDGAR | +3.96% | -2.50% | |
| Form 10-Q Prelude Therapeutics For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.98% | +4.19% | |
| Form 8-K Prelude Therapeutics For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -2.98% | +4.19% | |
| Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -2.98% | +4.19% | |
| Form 8-K Prelude Therapeutics For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.61% | |
| Prelude Therapeutics to Participate in Upcoming Healthcare Conferences | Press release | GlobeNewswire | +0.00% | +1.78% | |
| Form 10-Q Prelude Therapeutics For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -6.45% | |
| Form 8-K Prelude Therapeutics For: May 06 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -6.45% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PRLD section they belong to.
Where else PRLD is measured.
PRLD earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Prelude Therapeutics Incorporated's median reaction calculated?
Every labeled PRLD news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 237 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of PRLD's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PRLD's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.